Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma

Huey Ling You, Wan Ting Huang*, Ting Ting Liu, Shao Wen Weng, Hock Liew Eng

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

1 Scopus citations

Abstract

The genetic status of candidate tumor suppressor genes (TSGs) at chromosome 3p has not yet been elucidated in intrahepatic cholangiocarcinoma (iCCA). Herein, we retrospectively investigated 32 fresh iCCA case samples from a single medical institution to clarify mutations of 11 TSGs by next-generation sequencing. Validation of the mutations was performed on the MassARRAY platform or by high-resolution melting curve analysis. We then integrated the gene mutations into copy number alterations at chromosome 3p that had been generated in a previous study using the same fresh iCCA samples, and correlated the integration results with the clinicopathologic features. Nine of the 32 (28.1%) iCCA patients had gene mutations at chromosome 3p, totaling 11 mutations across five genes. Those included five (15.6%) BAP1 mutations, two each (6.3%) of CACNA2D3 and RASSF1 mutations, and one each (3.1%) of ATG7 and PLCD1 mutations. Six (18.8%) cases had concurrent loss of chromosome 3p and gene mutations. Patients with TSG mutations had shorter disease-free and survival times than those without the mutations. Our data showed that iCCA patients with TSG mutations at chromosome 3p faced an adverse prognosis. BAP1 was the common target of mutational inactivation and may be a principal driver of 3p21 losses.

Original languageEnglish
Pages (from-to)249-254
Number of pages6
JournalExperimental and Molecular Pathology
Volume103
Issue number3
DOIs
StatePublished - 12 2017

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Keywords

  • Chromosome 3p
  • Intrahepatic cholangiocarcinoma
  • Tumor suppressor genes

Fingerprint

Dive into the research topics of 'Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma'. Together they form a unique fingerprint.

Cite this